Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants may be included if they meet all of the following inclusion criteria prior to randomization:~1. Male or female participants ≥18 years of age.~2. History of HeFH with a diagnosis of HeFH by genetic testing; and/or a documented history of untreated LDL-C of \>190 mg/dL, and a family history of familial hypercholesterolemia, elevated cholesterol or early heart disease that may indicate familial hypercholesterolemia.~3. Serum LDL-C ≥2.6 millimoles (mmol)/liter (L) (≥100 mg/dL) at screening.~4. Fasting triglyceride \<4.52 mmol/L (\<400 mg/dL) at screening.~5. Participants on statins should be receiving a maximally tolerated dose.~6. Participants not receiving statins must have documented evidence of intolerance to all doses of at least 2 different statins.~7. Participants on lipid-lowering therapies (such as a statin and/or ezetimibe) should be on a stable dose for ≥30 days before screening with no planned medication or dose change during study participation.~Exclusion Criteria:~Participants will be excluded from the study if any of the following exclusion criteria apply immediately prior to randomization:~1. New York Heart Association (NYHA) class IV heart failure.~2. Uncontrolled cardiac arrhythmia~3. Uncontrolled severe hypertension~4. Active liver disease~5. Females who are pregnant or nursing, or who are of childbearing potential and unwilling to use at least 2 methods of highly effective contraception (failure rate less than 1% per year) (combined oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, or intrauterine device) for the entire duration of the study. Exemptions from this criterion:~   1. Women \>2 years postmenopausal (defined as 1 year or longer since last menstrual period) AND more than 55 years of age.~  2. Postmenopausal women (as defined above) and less than 55 years of age with a negative pregnancy test within 24 hours of randomization.~  3. Women who are surgically sterilized at least 3 months prior to enrollment.~6. Males who are unwilling to use an acceptable method of birth control during the entire study period (condom with spermicide).~7. Treatment with other investigational products or devices within 30 days or 5 half-lives of the screening visit, whichever is longer.~8. Treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inclisiran (Type: EXPERIMENTAL): Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90 then every 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered as SC injections of saline solution on Day 1, Day 90 then every 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete